Scott Boyken is the founder of Lyell Immunopharma. Lyell Immunopharma has raised $30M in total funding. Latest round: Series A.
Scott Boyken is the CSO and a co-founder of Outpace Bio, a spinout from Lyell Immunopharma that focuses on designing new proteins to solve problems in cell therapies. Outpace Bio raised $30 million in Series A funding. Previously, Boyken trained at the Institute for Protein Design at the University of Washington, where he co-designed the co-LOCKR protein 'computer.'
Full founder directory · Investor directory · Company funding database · Fundraising library